START Madrid is dedicated to the conduct of Phase I Clinical Trials of novel anticancer agents.

START Madrid currently has two Phase I Oncology Units: START Madrid-CIOCC (Centro Intengral Oncológico Clara Campal), which opened in 2008, and START Madrid-FJD (Hospital Fundación Jiménez Díaz), which opened in 2014. The two Madrid sites are designed to work together synergistically enabling START Madrid to provide all patients in Madrid and abroad to participate in a Phase I study of innovative drugs, regardless of their health coverage system and without exception: The National Public Health System in START Madrid-FJD (at Hospital Fundación Jiménez Díaz), and the Private Health System in START Madrid-CIOCC (at Centro Intengral Oncológico Clara Campal).

START Madrid were the first global site partner of START San Antonio (USA).  This International program further advances START’s mission of accelerating the development of anticancer drugs through a dedicated 24-hour a day network of START Centers operating in different time zones around the world.

Due to the work of scientists like those at START San Antonio, START Midwest and START Madrid, real progress is being made against cancer. Through the hard work of these physicians and the continuing advances in technology we are able to improve the tools to understand, detect, and diagnose cancer. Today, people with cancer are living longer than ever before with a better quality of life.

Our Mission

The mission of START is to accelerate the development of new anticancer drugs that will improve the quality of life and survival for patients with cancer. Our drug development program is not only furthering cancer research, but also offers hope to patients facing the toughest cancer battles.